Targeting the proteasome in cancer therapy: development and future opportunities in natural products
Frontiers in Pharmacology · 04.05.2026 · 17
DOI: 10.3389/fphar.2026.1806787 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 04.05.2026. Verfasst von Xiu Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 246 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The ubiquitin–proteasome pathway is a critical therapeutic target in malignancies, particularly multiple myeloma. The development of proteasome inhibitors (PIs) has marked a milestone in multiple myeloma therapy and now constitutes the backbone of frontline treatment regimens. However, primary and acquired resistance remain a major challenge, underscoring the need to identify new PIs as well as agents that can resensitize resistant cells.
Method
This review provides an overview of the current clinical applications of PIs and offers a comprehensive summary of natural products that either directly target the proteasome or enhance cellular sensitivity to PIs. Relevant clinical trials and literature published up to 2025 were retrieved from PubMed, Web of Science, Google Scholar, and ClinicalTrials.gov , focusing on the biological and pharmacological activities, structure-activity relationships, and clinical outcomes.
Results
In this review, we summarize the current clinical applications of PIs and specifically highlight the discovery of natural products that directly target the proteasome or enhance cellular sensitivity to PIs. We also discuss the clinical progress of marizomib, the only natural product-derived PI, that has advanced to clinical trials. Despite existing challenges, natural product-derived PIs hold significant potential for the development of next-generation therapies that can overcome resistance and improve clinical outcomes.
Conclusion
The development of novel natural product-derived PIs and rational combination strategies offers promising opportunities for overcoming resistance in cancer therapy. Although challenges remain, the remarkable structural diversity of natural products provides a rich reservoir for drug discovery, underscoring the importance of continued exploration and innovation in this field.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug, West China School of Pharmacy, Sichuan University, Chengdu…
- Center for Translational Research in Hematological Malignancies, Houston Methodist Neal Cancer Center, Houston Methodist Academic Institute, Houston, TX, United States.
Zitieren
APA
Zhao, X., Liu, S., Zeng, X., Liao, Y., Zhang, M., Wang, Q., Zhang, D., Chen, Q., Xian, M., & Qin, Y. (2026). Targeting the proteasome in cancer therapy: development and future opportunities in natural products. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1806787
Vancouver
Zhao X, Liu S, Zeng X, Liao Y, Zhang M, Wang Q, et al. Targeting the proteasome in cancer therapy: development and future opportunities in natural products. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1806787
BibTeX
@article{Zhao2026,
author = {Zhao, Xiu and Liu, Shanshan and Zeng, Xinrui and Liao, Yu and Zhang, Mao and Wang, Qiang and Zhang, Dan and Chen, Qifeng and Xian, Miao and Qin, Yong},
title = {Targeting the proteasome in cancer therapy: development and future opportunities in natural products},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1806787}
}
EUVIMED